For citations:
Lomakin N.V., Bakirov B.A., Musaev G.H., Popov V.V., Smolyarchuk E.A., Linkova Yu.N., Bogdan D.V., Eremeeva A.V., Pukhtinskaia P.S., Morozova M.A., Zinkina-Orikhan A.V., Lutckii A.A. Levilimab clinical efficacy for interleukin-6 receptor inhibition in COVID-19 and its potential for treating cytokine release syndrome of other aetiologies. Biological Products. Prevention, Diagnosis, Treatment. 2022;22(4):446-459. (In Russ.) https://doi.org/10.30895/2221-996X-2022-22-4-446-459
Email this article 